Successful collaboration between Aleva Neurotherapeutics and DIXI Medical

Adept Neuro has exclusive intellectual property rights of Aleva Neurotherapeutics in the fields of epilepsy. DIXI Medical ensures the exclusive production and distribution of the Adept Neuro’s products, while DIXI Holding will finance the joint venture and gradually become the sole shareholder. 

As Adept has reached a significant milestone in the development of the MEMS-enabled smart SEEGs electrodes, DIXI Medical will invest a second tranche and is now targeting regulatory certifications, both in the US and the EU. It expects to have its new product generation on the US market in H1’2022 and a follow-up product with enhanced sensing capabilities that will be a game-changer for practitioners and patients by H2’2023.

“We are impressed how far we have come in the past 24 months and are pleased to switch our collaboration into higher gear with this next investment tranche," said Frederic Koehn, CEO of DIXI Medical. “We have been equally impressed with what Adept’s MEMS technology can do in providing new product features and capabilities for our existing customers. Dixi is continuing to invest into new manufacturing and supply infrastructure in order to be ready for the commercial-scale production of SEEGs electrodes for drug-refractory epilepsy patients."

Andre Mercanzini, Founder of Aleva Neurotherapeutics and Executive Chairman of Adept Neuro, added: “Our team at Adept has been moving quickly and we are well ahead of our own optimistic expectations. Dixi has been a formidable partner, and their existing sales channel and loyal customer base ensures a rapid uptake of our innovative SEEGs solutions. Furthermore, Dixi’s manufacturing base has been able to quickly absorb the advantages of MEMS technology on their assembly lines, which further ensures quality and time to market for the technology."

Adept Neuro develops a new generation of intracerebral stereoelectroencephalography (SEEG) electrodes to facilitate localization and thermocoagulation of epileptogenic zones. The Company has exclusive access to Aleva Neurotherapeutics´ MEMS technology in epilepsy, which allows great flexibility of design and miniaturization, and also benefits from DIXI Medical´s leadership in the manufacturing of intracerebral electrodes for SEEG.